BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31313559)

  • 1. Imatinib Mesylate Induced Erythroderma.
    Lunge S; Bhise R
    J Assoc Physicians India; 2018 Dec; 66(12):79-80. PubMed ID: 31313559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rare case of imatinib-induced erythroderma.
    Verma R; Vasudevan B; Pragasam V; Neema S
    Indian J Pharmacol; 2013; 45(6):634-5. PubMed ID: 24347779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate induced erythroderma: A rare case series.
    Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
    J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythroderma: An unusual manifestation of imatinib - A rare case report.
    Kataria P; Patel A; Kendre P; Tahiliani N; Mule T; Bohra M
    J Cancer Res Ther; 2022; 18(1):253-256. PubMed ID: 35381793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate induced erythroderma.
    Sanghavi SA; Dongre AM; Khopkar US
    Indian J Dermatol Venereol Leprol; 2012; 78(3):408. PubMed ID: 22565463
    [No Abstract]   [Full Text] [Related]  

  • 6. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
    Dervis E; Ayer M; Akin Belli A; Barut SG
    Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DRESS syndrome induced by imatinib.
    Kaur S; Singh S; Singh R; Singla P
    J Postgrad Med; 2021; 67(3):158-163. PubMed ID: 34427280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desensitization to imatinib in patients with leukemia.
    Nelson RP; Cornetta K; Ward KE; Ramanuja S; Fausel C; Cripe LD
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):216-22. PubMed ID: 16937754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
    Vano-Galvan S; Fernandez-Guarino M; Henriquez-Santana A; De Las Heras E; Calbacho M; Jaen P
    Eur J Dermatol; 2007; 17(6):538-9. PubMed ID: 17951138
    [No Abstract]   [Full Text] [Related]  

  • 10. Cystic acne due to imatinib therapy for chronic myelocytic leukemia.
    Hwang A; Iskandar A; Del Rosario M; Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):972-974. PubMed ID: 29498323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
    Vinay K; Yanamandra U; Dogra S; Handa S; Suri V; Kumari S; Khadwal A; Prakash G; Lad D; Varma S; Malhotra P
    Int J Dermatol; 2018 Mar; 57(3):332-338. PubMed ID: 29266186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
    Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
    Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature.
    Di Tullio F; Mandel VD; Scotti R; Padalino C; Pellacani G
    Int J Dermatol; 2018 Jul; 57(7):784-790. PubMed ID: 29417559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine tumor of cecum in patient treated with imatinib mesylate for blastic phase of chronic myeloid leukemia.
    Novaković S; Kovač Peić A; Holik H; Coha B
    Acta Clin Belg; 2017 Dec; 72(6):461-464. PubMed ID: 28420292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate-induced pseudoporphyria in a patient with chronic myeloid leukemia.
    Batrani M; Salhotra M; Kubba A; Agrawal M
    Indian J Dermatol Venereol Leprol; 2016; 82(6):727-729. PubMed ID: 27716725
    [No Abstract]   [Full Text] [Related]  

  • 17. Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
    Musolino C; Allegra A; Mannucci C; Russo S; Alonci A; Maisano V; Calapai G; Gangemi S
    Turk J Haematol; 2015 Jun; 32(2):168-71. PubMed ID: 26316486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
    Brouard MC; Prins C; Mach-Pascual S; Saurat JH
    Dermatology; 2001; 203(1):57-9. PubMed ID: 11549802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib-induced pseudoporphyria.
    Martinez-Mera C; Capusan TM; Herrero-Moyano M; Urquía Renke A; Steegmann Olmedillas JL; de Argila D
    Clin Exp Dermatol; 2018 Jun; 43(4):463-466. PubMed ID: 29315788
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
    Gambillara E; Laffitte E; Widmer N; Decosterd LA; Duchosal MA; Kovacsovics T; Panizzon RG
    Dermatology; 2005; 211(4):363-5. PubMed ID: 16286749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.